Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years
Arthritis Care & Research · 2026
DOI: 10.1002/acr.80115 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Lucy R Wedderburn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity and Inflammation Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, Londo…. Hauptthemen laut MEDLINE: Myositis, Dermatomyositis. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Intramural Research Programs of the National Institute of Environmental Health Sciences, National Instititues of Health.
Abstract (Originalsprache)
The juvenile idiopathic inflammatory myopathies (JIIMs) are rare, serious, multisystem autoimmune diseases affecting children and young people. Fifty years ago, the prognosis for these conditions was poor, with high morbidity and mortality, and very few treatments were available. Since then, there has been major growth in our understanding of the pathogenesis and evidence basis for treatment. Early descriptions considered juvenile dermatomyositis (JDM) to be essentially one disease. Our modern understanding has shown that there are different types of JIIMs, and that although JDM remains the most prevalent, even JDM itself is highly heterogenous. Much progress has been made possible through concomitant growth in the research community with a focus on JIIMs and the fact that the myositis research and clinical communities are highly collaborative internationally. Here, we review the growing understanding of the different types of childhood myositis; the developments in classification, driven in part by recognition of associations of particular phenotypes with specific myositis autoantibodies; the novel insights into pathogenesis of the JIIMs; the therapeutic targets that these have revealed; and the evidence for, and development of, modern treatment care pathways, which have changed radically in recent decades. This has resulted in improved outcomes for children and young people with JIIMs and hope for further groundbreaking developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infection, Immunity and Inflammation Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London, United Kingdom.
- Centre for Adolescent Rheumatology at University College London, University College London Hospitals and Great Ormond Street Hospital, London, United Kingdom.
- NIHR Biomedical Research Centre at Great Ormond Street Hospital, NHS Foundation Trust, London, United Kingdom.
- Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Institute of Health Policy Evaluation & Management, University of Toronto, Toronto, Ontario, Canada.
- Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland.
ORCID-Profile: Lucy R Wedderburn, Brian M Feldman, Lisa G Rider
Förderung
- Intramural NIH HHS
- Intramural Research Programs of the National Institute of Environmental Health Sciences
- National Instititues of Health
Zitieren
APA
Wedderburn, L. R., Feldman, B. M., & Rider, L. G. (2026). Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years. Arthritis Care & Research. https://doi.org/10.1002/acr.80115
Vancouver
Wedderburn LR, Feldman BM, Rider LG. Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years. Arthritis Care & Research. 2026. doi:10.1002/acr.80115
BibTeX
@article{Wedderburn2026,
author = {Wedderburn, Lucy R and Feldman, Brian M and Rider, Lisa G},
title = {Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.80115}
}
EUVIMED